ClinConnect ClinConnect Logo
Search / Trial NCT01021072

A First in Man Study of MABp1 in Patients With Advanced Cancers

Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Nov 24, 2009

Trial Information

Current as of July 24, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • pathologically confirmed advanced malignancy that is metastatic or unresectable and which is refractory to standard therapy or for which thee is no standard therapy that provides benefits for \>/= 3 months
  • measurable or non-measurable disease at baseline
  • at least 4 weeks since the last dose of chemotherapy, radiation therapy, immunotherapy, or surgery; at least 6 weeks for therapy which is known to have delayed toxicity; at least 4 weeks since treatment with biologic/targeted therapies; at least 2 weeks since last hormonal therapy
  • will not be treated with any other chemotherapy, immunotherapy, radiotherapy or investigational drug while enrolled on this protocol
  • age \>/= 18 year, male or female
  • Eastern Cooperative Oncology Group performance status 0,1,or 2
  • Serum potassium and magnesium levels within institutional normal limits. Total serum calcium or ionized calcium level must be greater than or equal to the low limit of normal.
  • Adequate renal function, defined by serum creating \</= 1.5 x ULN
  • Adequate hepatic function
  • Adequate bone marrow function WOCBP, a negative serum pregnancy test result at screening.
  • WOCBP or men whose sexual partners are WOCBP who are willing to use an acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 3 months after the last dose of study medication
  • Signed and dated IRB approved ICF before any protocol specific screening procedures are performed
  • Exclusion Criteria:
  • serious uncontrolled medical disorder or active infection which would impair the patient to receive protocol therapy.
  • Uncontrolled or significant cardiovascular diseae
  • dementia or altered mental status that would prohibit the understanding or rendering of informed consent
  • not recovered from the adverse effects of prior therapy at the time of enrollment \</= grade 1
  • symptomatic brain metastases which are either untreated or uncontrolled by surgery and or radiotherapy
  • received extensive prior radiation therapy to the bone marrow
  • immunocompromised, including subjects know to be infected with HIV
  • history of hypersensitivity to compounds of similar chemical or biologic composition to the antibody women how are pregnant or breastfeeding
  • WOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 3 months after the last dose of study medication

About Janssen Research & Development, Llc

Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, is a leading pharmaceutical company dedicated to advancing innovative therapies in multiple therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular health. With a strong commitment to scientific excellence and patient-centered research, Janssen leverages cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. The company is focused on addressing unmet medical needs through rigorous clinical trials and a robust pipeline, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Houston, Texas, United States

Houston, Texas, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials